Pentavalent Market Report 2026

The pentavalent market size has grown steadily in recent years. It will grow from $2.7 billion in 2025 to $2.83 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to rising infant mortality rates, limited access to vaccines, prevalence of rotavirus infections, government vaccination initiatives, global public health campaigns.

The pentavalent market size is expected to see steady growth in the next few years. It will grow to $3.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to technological advancements in vaccine formulation, increasing healthcare expenditure, expansion of immunization programs in developing countries, partnerships between pharma companies, integration of digital tracking for vaccine coverage. Major trends in the forecast period include increased infant immunization programs, government funding for vaccine development, expansion of public health infrastructure, rising awareness of rotavirus prevention, growth of cold chain logistics.

The rising prevalence of diphtheria is expected to drive growth in the pentavalent vaccine market. Diphtheria, caused by the bacterium Corynebacterium diphtheriae, is a severe and highly contagious disease that can lead to breathing and swallowing difficulties, as well as skin ulcers. Pentavalent vaccines protect children against diphtheria along with four other diseases through a three-dose immunization schedule. Consequently, the increasing prevalence of diphtheria has heightened demand for pentavalent vaccines. For instance, in July 2025, according to the European Centre for Disease Prevention and Control, a Europe-based government agency, Germany reported 126 laboratory-confirmed cases of C. diphtheriae ST574, compared with 55 cases in 2022, 49 in 2023, 18 in 2024, and at least 4 cases in 2025. Therefore, the rising prevalence of diphtheria is propelling the pentavalent vaccine market.

Rising healthcare expenditure is also expected to support growth in the pentavalent market. Healthcare expenditure encompasses the total financial and resource investments made in healthcare services over a specific period, including vaccine development, production, distribution, and administration. Increased spending enhances accessibility and adoption of vaccines, including pentavalent formulations. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency, U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per capita. Therefore, rising healthcare expenditure is driving the expansion of the pentavalent vaccine market.

Key companies in the pentavalent market are focusing on the development of advanced combination vaccines that provide protection against multiple diseases. Pentavalent vaccines are designed to immunize individuals against five distinct diseases in a single formulation. For example, in October 2023, Pfizer, a US-based pharmaceutical company, announced FDA approval for its pentavalent vaccine, Penbraya. This is the first and only pentavalent vaccine providing protection against the five most prevalent meningococcal serogroups - A, B, C, W-135, and Y - for individuals aged 10 to 25 years. The vaccine combines elements from the Trumenba meningococcal group B vaccine and the Nimenrix conjugate vaccine for serogroups A, C, W-135, and Y. Penbraya has demonstrated effectiveness in preventing the majority of invasive meningococcal disease cases globally.

Major companies operating in the pentavalent market are Pfizer Inc., Merck & Co Inc., Sanofi SA, GlaxoSmithKline plc, Shandong Xinhua Pharmaceutical Company Limited, PT Bio Farma (Persero), Shantha Biotechnics Limited, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co Ltd., Changchun Changsheng Biotechnology Co Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, PanGen Biotech Inc., Bharat Biotech International Limited, Vacsera Ltd., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co Ltd.

Asia-Pacific was the largest region in the pentavalent market in 2025. The regions covered in the pentavalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pentavalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have posed challenges for the pentavalent vaccine market by increasing the cost of imported raw materials and vaccine components, thereby affecting production efficiency. Regions like Asia-Pacific and Europe, which are major suppliers of vaccine ingredients, have been most impacted, particularly in hospital and retail pharmacy segments. While tariffs may temporarily increase costs, they also encourage local manufacturing initiatives and supply chain diversification, potentially boosting domestic production and reducing long-term dependency on imports.

The pentavalent market research report is one of a series of new reports that provides pentavalent market statistics, including pentavalent industry global market size, regional shares, competitors with a pentavalent market share, detailed pentavalent market segments, market trends and opportunities, and any further data you may need to thrive in the pentavalent industry. This pentavalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pentavalent vaccines are designed to protect children from life-threatening diseases. They are used to prevent rotavirus infections in infants and young children, which can cause fever, vomiting, and diarrhea. Administered as part of routine immunization programs, these vaccines provide broad, early protection against major infectious diseases in children.

The main types of pentavalent vaccines include sodium stibogluconate and meglumine antimoniate. Lyophilization, a process that removes water, is often used to preserve perishable products, extend shelf life, or facilitate transportation. The vaccines are available in various formulations, including lyophilized and liquid forms, and are used across hospitals, retail pharmacies, and online pharmacies.

The pentavalent market consists of sales of pentavalent vaccines such as those for diphtheria, pertussis, tetanus, hepatitis B, and Hib that treat a child against potentially fatal diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.